Skip to content

Iron Supplement to Improve Iron Status Following Bariatric Surgery

Comparison of Iron Supplement Formulations to Improve Iron Status Following Roux-en-Y and Sleeve Gastrectomy Bariatric Surgery

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02404012
Enrollment
64
Registered
2015-03-31
Start date
2014-11-30
Completion date
2021-12-31
Last updated
2022-08-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anemia, Iron Deficiency

Keywords

iron deficiency, sleeve gastrectomy, gastric bypass, bariatric surgery

Brief summary

There is a high prevalence of iron deficiency in patients who undergo bariatric surgery and effective therapies are lacking. Thus, there is a critical need for an effective, non-invasive, and inexpensive form of iron supplementation to treat iron deficiency and improve tolerance, the associated cognitive symptoms, and quality of life in the bariatric surgery patient population. Often, patients do not participate in bariatric programs, are not compliant, and/or are lost to follow-up. If there is a more effective and evidence-based guideline for repletion of iron deficiency, patients are more likely to be compliant. Therefore, in a randomized controlled study, the investigators propose to test the effectiveness of various iron formulations versus ferrous sulfate, which is the standard of care, for oral iron supplementation of iron deficient patients who have had RYGB or SG bariatric surgery. By randomizing patients into the two groups, the investigators will be able to determine the most effective regimen to improve blood biomarkers of iron status, cognitive function, and quality of life. Other outcomes will include adverse effects and compliance to the supplementation. The investigators will also analyze three-day food records to determine the contribution of dietary factors to changes in iron status. To test for improvement of iron status, serial blood draws will be performed during a time period of \ 10 weeks. Serial blood draws from iron deficient patients have routinely been performed in past studies and have not been found to be harmful. Because this is a relatively short study (10 weeks), subjects will be able to recover quickly from the blood loss during the study. The investigators expect to find that iron supplementation with organic formulations of iron will be as effective than ferrous sulfate for repletion of iron deficiency, and they will be better tolerated. This project will address a significant health issue in individuals who have had bariatric surgery, which is a growing population in the United States. It is estimated that almost 1.5 million individuals have undergone bariatric surgery since the year 1990.

Detailed description

Objectives: 1. To determine the most effective oral iron supplementation regimen for repletion of iron deficiency in patients who have had gastric bypass or sleeve gastrectomy. In iron deficient patients, two supplement regimens will be compared: 1. Ferrous sulfate 65 mg t.i.d. (standard of care / control), which is elemental iron 2. AspironTM, which is an organic formulation of iron Primary outcomes will be reference indices of iron status: * Ferritin, TIBC, sTfR, and sTfR:ferritin ratio * Secondary outcomes will be: * measures of anemia, determined by blood hemoglobin concentrations * measures of cognitive function via several computerized tests on working memory, sustained attention, and spatial memory * fatigue by Multidimensional Fatigue Inventory questionnaire * Quality of life by SF-36 Survey Safety outcomes will be: • adverse events, compliance, measures of iron toxicity, and liver enzymes 2. In the same subjects undergoing iron supplementation described in Aim 1, to determine the contribution of dietary factors (including heme and non-heme iron intake, and intake of enhancers and inhibitors of iron absorption) to changes in iron status.

Interventions

DIETARY_SUPPLEMENTOral iron supplementation

Participants will be provided supplementation for 8 weeks

Sponsors

Indiana University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Subject has a history of RYGB or SG weight loss surgery at least 6 months ago * Subject meets at least 2 of the 4 previously mentioned conditions classifying them as iron deficient * Subject is female * Subject is at least 18 but not more than 65 years of age (post-menopausal status is an

Exclusion criteria

) * Subject has signed an informed consent.

Design outcomes

Primary

MeasureTime frameDescription
Iron status8 weeksFerritin, TIBC, sTfR

Secondary

MeasureTime frame
Anemia assessed by Hemoglobin concentrations8 weeks

Other

MeasureTime frame
Safety outcomes assessed by adverse events, compliance8 weeks

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 10, 2026